TriangleSelinexor 60 MG (NCT04661137)
Selinexor 60 MG trial for Multiple Myeloma (NCT04661137). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults whose multiple myeloma progresses or resists treatment with carfilzomib, pomalidomide or daratumumab.
The idea: add oral selinexor and dexamethasone to the corresponding drug. Selinexor blocks a protein that moves growth-control proteins out of the cell nucleus. Treatment is assigned by prior therapy, not randomly. Researchers measure responses; doses and schedules differ between groups.
This phase 2 study plans 96 patients. Noa Biran leads it for Hackensack Meridian Health; two US sites are recruiting, in Hackensack and Washington, D.C.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.